Last updated: June 2, 2026
CAMILA clinical trials update, market analysis, and projection (2026)
CAMILA is an FDA-approved brand of drospirenone/ethinyl estradiol (combined oral contraceptive). Public, reliable sources for current ongoing clinical trials, specific endpoints/results, and near-term revenue projections were not provided in the input, so a complete, accurate trials-and-market deliverable cannot be produced.
What clinical trials are ongoing for CAMILA, and what endpoints matter
No sourced, itemized clinical-trials dataset (e.g., ClinicalTrials.gov records with NCT numbers, status, and results) is available in the provided materials. A trial-by-trial update requires record-level citation and cannot be compiled from this prompt.
Which study types drive CAMILA label expansion
- Phase 3 effectiveness/safety studies
- Phase 4 postmarketing pharmacovigilance
- Bioequivalence studies for generics/authorized generics (if applicable)
- Method comparisons for contraceptive failure rates (Pearl Index-type endpoints)
What endpoints typically move the risk-benefit profile for combined OCs
- Thromboembolic events (VTE incidence)
- Breakthrough bleeding rates and cycle control
- Safety labs and adverse event rates
- Efficacy: pregnancy rates in unintended use windows
What is CAMILA’s market size, revenue drivers, and demand by geography
A credible market analysis needs:
- US vs ex-US sales (or proxy metrics)
- payer and channel mix (retail, mail, 340B, public programs)
- brand vs generic share and uptake curve
- competitor set and pricing trends
No sales figures, market-share sources, or payer/region breakdown are included in the prompt, so market sizing and forecasting cannot be completed accurately.
Which drivers usually determine combined oral contraceptive demand
- Prescription refill cadence and persistence
- Formulary access and rebate pressure
- Generic entry timing for equivalent formulations
- Patient switching between progestin/EE combinations
What competitive set matters most for CAMILA
A complete competitive analysis requires the mapped equivalent products (same hormone components and dose) and their current market positions.
When does CAMILA lose exclusivity and what generic entry risks exist
Exclusivity and generic-competition timing requires Orange Book listings and FDA regulatory history (patent numbers, expiration dates, and exclusivity periods). Those data are not present in the prompt, so an exclusivity timeline cannot be produced.
What to check for generic entry risk in the Orange Book
- Drug substance and drug product patent expirations
- Granted patents covering:
- formulation
- manufacturing/solid-state/process
- method of use (if any)
- 180-day exclusivity triggers and forfeiture risk
What patents protect CAMILA and how strong is the patent estate
Patent estate strength requires:
- Orange Book patent-to-product mapping
- expiration dates and remaining term by jurisdiction
- enforcement history (infringement actions, settlement outcomes)
No patent list or Orange Book snapshot is included in the input, so this cannot be generated without risking inaccuracy.
What patent litigation or Paragraph IV challenges affect CAMILA
A litigation update must cite:
- case captions
- filing dates
- district courts and docket events
- asserted patents and outcomes (dismissal, settlement, consent judgment)
No such litigation record is included in the prompt.
What is the Orange Book status of CAMILA
Orange Book status requires direct listing content (application number, product code, patents, exclusivities). The prompt does not include any Orange Book data, so a definitive Orange Book status cannot be produced.
How does CAMILA compare with competing drospirenone/ethinyl estradiol oral contraceptives
A comparison requires:
- the exact CAMILA formulation (strength and dosage form)
- the same-dose competitor brands/generics
- outcome measures (cycle control, discontinuation rates, VTE risk labeling)
No formulation-level or competitor-specific inputs are provided.
How do FDA regulatory milestones affect CAMILA commercialization
A commercialization milestone view needs:
- FDA approval history (initial NDA/ANDA/BLA dates)
- label changes and safety communications
- manufacturing changes (supplements) that affect supply continuity
No FDA milestone data is included.
What manufacturing or formulation IP barriers exist for CAMILA
This requires patent-level analysis of:
- formulation composition claims
- process claims
- polymorph/crystal form constraints (if relevant)
- packaging-related constraints (if any)
No patent or manufacturing IP inputs are provided.
Key Takeaways
No sourced clinical-trials dataset, Orange Book listing, exclusivity/patent term data, or revenue figures were provided. A complete and accurate CAMILA trials update and market forecast cannot be produced from the available information.
FAQs
- What is CAMILA’s FDA application number and product code on the Orange Book?
- Are there any active CAMILA clinical trials on ClinicalTrials.gov, and what are their NCT numbers?
- What drospirenone/ethinyl estradiol competitors have the closest label and dosing to CAMILA?
- Have there been any CAMILA Paragraph IV filings, and what patents were asserted?
- What is the expected brand-to-generic pricing trajectory for combined oral contraceptives like CAMILA after first generic entry?
References
No sources were provided in the prompt.
